DOCSLIB.ORG

Head of Structural Biology Division Recruitment

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Head of Structural Biology Division Recruitment Head of Structural Biology WALTER AND ELIZA HALL INSTITUTE Information for prospective candidates 160331 CANCER | IMMUNE DISORDERS | INFECTIOUS DISEASE OUR MISSION INSTITUTE AT A GLANCE Mastery of disease through discovery 2015 OUR VISION To be an innovative medical research Institute that enriches society through discovery and education and improves health outcomes through translation staff1000 and students OUR VALUES ● Pursuit of excellence 9staff and31 students diseases 40+impacted by institute research 3publications81 ● Integrity and mutual respect ● Collaboration and teamwork ● Creativity diseases40+ impacted ● by Institute Accountability research ● Contribution to society OUR STRATEGIC GOALS 9staff and31 students diseases 40+impacted by institute research 3publications81 Strategic goals of the Walter and Eliza Hall Institute national1 and0 international0 trials of Medical Research Strategic Plan (2015 – 2020) based on institute discoveries publications86 institute with1 and 3 visiting0 speakers people5 came to5 an event1 at 6the institute are: impact factor >10 1. make discoveries that shape contemporary scientific thinking, increase understanding and improve prevention, diagnosis and treatment publications410 of cancer, immune disorders and infectious 9staff and31 students diseases 40+impacted by institute research 3publications81 diseases; 2. educate and train the next generation of world class scientists and attract, develop and retain the best and brightest workforce; national1 and0 international0 trials based on institute discoveries institute1 and3 visiting0 speakers people5 came to5 an event1 at 6the institute 3. provide a vibrant and inspiring organisational culture that encourages, promotes and rewards national100 and excellence, creativity, mutual respect and international trials collaboration; based on Institute discoveries 4. engage with our stakeholders to improve scientific outcomes, build support and secure national1 and0 international0 trials resources for the Institute and medical research; based on institute discoveries institute1 and3 visiting0 speakers people5 came to5 an event1 at 6the institute and 5. build infrastructure, professional services and funding Patents37 granted in 2015 2 | Head of Structural Biology, Walter and Eliza Hall Institute – Information for prospective candidates ABOUT THE INSTITUTE HEALTH IMPACTS The Walter and Eliza Hall Institute is Australia’s oldest medical research institute. It The Institute is committed to was founded in 1915 with financial support from a trust established by Eliza Hall, making fundamental scientific following the death of her husband Walter. The vision was for an institute that ‘will be discoveries that can be translated the birthplace of discoveries rendering signal service to mankind in the prevention and to better treatments, bringing real removal of disease and the mitigation of suffering’. benefits to the community on a Throughout the Institute’s history its researchers have focused on understanding the global scale. Clinical trials based fundamental principles of medical biology and using this knowledge to mitigate disease. on discoveries made at the Institute Our current researchers and students continue to work on solving basic science include trials of vaccines for coeliac questions through curiosity-driven research. We are committed to innovative science disease, diabetes and malaria; that expands and improves our understanding of basic human biology and the and trials of a new class of anti- disruptions to systems that cause disease. Our scientists also undertake blue-sky cancer drugs, called BH3-mimetics, research that creates and explores new areas of biology. for treating people with leukaemia Three nationally and globally significant areas of health have been long-term, central and other cancers. interests of our research: • cancer – understanding the basic processes that are disrupted to generate cancer cells and how these can be targeted to treat disease; CANCER • immunology – discovering how the body fights infection, and how errors in the Bowel cancer immune system lead to disease; and Brain cancer • infectious diseases – today with a focus on globally significant pathogens, Breast cancer especially malaria and chronic infections. Leukaemia We take a multidisciplinary approach to addressing major research questions, Lung cancer integrating expertise in bioinformatics, clinical translation, genomics, medicinal Lymphoma chemistry, personalised medicine, proteomics, structural biology and systems biology. Melanoma The Institute offers postgraduate training as the Department of Medical Biology of Myeloma The University of Melbourne, and is affiliated with The University of Melbourne and Myeloproliferative disease The Royal Melbourne Hospital. The Institute also has strong ties with many research organsations in Melbourne and around the world. Ovarian cancer Pancreatic cancer INSTITUTE LEADERSHIP Prostate cancer Stomach cancer Director - Professor Douglas J Hilton AO BSc Mon BSc(Hons) PhD Melb FAA FTSE FAHMS IMMUNE DISORDERS Deputy Director/Scientific Strategy - Professor Alan Cowman BSc(Hons) Griffith PhD Melb FAA Allergy Asthma Deputy Director/Science Integrity and Ethics - Professor David Vaux Coeliac disease BMedSci MBBS PhD Melb FAA FAHMS Inflammatory bowel disease Deputy Director/Strategy and Operations - Ms Samantha Ludolf Lupus BA(Hons) Lincoln MEnterp Melb Multiple sclerosis Institute Board President - Mr Chris Thomas Psoriasis BCom (Hons) MBA Melb FAICD Rheumatic fever and rheumatic heart disease Rheumatoid arthritis Sepsis Type 1 and type 2 diabetes INFECTIOUS DISEASE Filariasis Hepatitis B HIV Leishmania Malaria Scabies Toxoplasmosis Tuberculosis Head of Structural Biology, Walter and Eliza Hall Institute – Information for prospective candidates | 3 STRUCTURAL BIOLOGY DIVISION – BACKGROUND AND ACHIEVEMENTS Since its establishment in 2001, the Walter and Eliza Hall Institute’s Structural Biology division has been a leading site for the analysis of proteins important for both therapeutic development and for the progression of structural biology for its own sake. The founding head of the division, Professor Peter Colman, brought with him a wealth of international structural biology and biotechnology experience and success. Professor Colman’s determination of the three-dimensional structure of influenza virus neuraminidase formed the basis for the world’s first anti-influenza drugs, which were developed by Biota Pharmaceuticals Inc. and Glaxo, who brought Relenza™ to the market. Professor Colman’s success was built on his broad collaborations, access to the best equipment and his fostering of talented researchers. At the Walter and Eliza Hall Institute, Professor Colman has recruited and mentored scientists with interests in the insulin receptor, the epidermal growth factor receptor (EGFR), cytokine signalling, apoptosis and medicinal chemistry. Under his leadership the division has grown from fewer than ten scientists and students to almost 100 researchers. The division was so successful that the medicinal chemistry expertise was able to form part of a new division at the Institute, the ACRF Chemical Biology division. The Structural Biology division currently has eight laboratory heads leading forty staff and students. Major collaborations have been established in cell surface biology, receptor and cytokine signalling and programmed cell death. Many world-first discoveries have been made by the division, including the first structures of the extracellular domain of the EGFR with its ligand, the full-length human gp130 cytokine receptor, insulin in complex with a portion of the extracellular domain of the insulin receptor, the extracellular domain of erbB2 , a SOCS3-JAK signalling complex, the activated pro-apoptotic Bcl-2 family proteins and the structures of T-cell signalling complexes and stem cell markers such as Lrig1. The division was also the site of the first structure of a potassium channel to be determined in Australia. These projects are empowered by collaborations with internationally successful scientists in other Walter and Eliza Hall Institute divisions, and more broadly with biologists across the globe. As well as supporting the establishment of the crystallography beamlines at the Australian Synchrotron, the division has been a premier site for the application of other state-of-the- art structural biology techniques including high-field NMR, microcalorimetry and biosensor analysis. Where new technologies have emerged, such as cryoelectron microscopy, the division has established connections to international sites and has championed the development of shared facilities in Australia. A major element in the success of the Structural Biology division is the enthusiasm of collaborating biologists within the Institute, and the overall environment of the Institute. Structural information produced by the division is used by biology colleagues at the Institute to improve understanding of disease processes, by Institute medicinal chemistry colleagues to develop drugs directed to the target structures and by Institute clinical colleagues working with Melbourne Health and the Victorian Comprehensive Cancer Centre to have the drugs tested in the clinic. For example, the division’s structural studies on the EGFR led to the discovery of the mechanism of action of a “tumour-specific” antibody, mAb806. This discovery encouraged the pharmaceutical development of the antibody, which has already benefited brain tumour patients.
Load more

Recommended publications
  • Respiratory Virusreport
    Surveillance Symposium Report Inside! See page 2. Respiratory Virus Report spring 2009 isirv International Symposium on Immune Correlates of Protection Against Influenza: Reassessing licensing requirements for seasonal and pandemic influenza vaccines 2-5 March 2010 Miami, Florida, United States In this issue: SPECIAL isirv International Symposium on Viral BULLETIN Respiratory Disease Surveillance ............ 2 In response to the ongoing John Watson recounts highlights from the meeting in Seville. influenza A (H1N1) outbreak, isirv has posted two new resource lists on In the Loop.................................................. 5 its website. These lists will facilitate Summaries of recent key literature in viral respiratory disease. access to current guidance and background information relative to isirv news ................................................... 6 this new public health threat. Immune Correlates Symposium announcement, updates on the Transmission and Mitigation Symposium, and Options VII. isirv is committed to providing Obituary: Graeme Laver, PhD, FRS .......... 8 accurate information to its Robert Webster eulogizes Australian researcher Graeme Laver, who made membership. Visit www.isirv.org for major contributions to our current understanding of influenza ecology more information and authoritative and antigenic drift, and to the development of subunit vaccines and sources of key professional influenza antiviral drugs information on the influenza A (H1N1) outbreak. Respiratory Virus Report spring 2009 Highlights of the isirv International Symposium on Viral Respiratory Disease Surveillance by John Watson, MB BS, MSc, FRCP, FFPH The surveillance symposium was a great success. Pilar Perez viral respiratory disease Brena of the National Centre for Microbiology at the Instituto surveillance, seasonal de Salud Carlos III, welcomed delegates to the “charming, and pandemic influenza mysterious, and warm” city of Seville, Spain.
    [Show full text]
  • Fas Ligand, Bcl-2, Granulocyte Colony-Stimulating Factor, and P38
    Fas Ligand, Bcl-2, Granulocyte Colony-Stimulating Factor, and p38 Mitogen-activated Protein Kinase: Regulators of Distinct Cell Death and Survival Pathways in Granulocytes By Andreas Villunger,* Lorraine A. O’Reilly,* Nils Holler,‡ Jerry Adams,* and Andreas Strasser* From *The Walter and Eliza Hall Institute, Melbourne, Victoria 3050, Australia; and the ‡Institute of Biochemistry, University of Lausanne, Epalinges CH-1066, Switzerland Abstract The short life span of granulocytes, which limits many inflammatory responses, is thought to be influenced by the Bcl-2 protein family, death receptors such as CD95 (Fas/APO-1), stress-acti- vated protein kinases such as p38 mitogen-activated protein kinase (MAPK), and proinflamma- tory cytokines like granulocyte colony-stimulating factor (G-CSF). To clarify the roles of these various regulators in granulocyte survival, we have investigated the spontaneous apoptosis of granulocytes in culture and that induced by Fas ligand or chemotherapeutic drugs, using cells from normal, CD95-deficient lpr, or vav-bcl-2 transgenic mice. CD95-induced apoptosis, which required receptor aggregation by recombinant Fas ligand or the membrane-bound ligand, was unaffected by G-CSF treatment or Bcl-2 overexpression. Conversely, spontaneous and drug-induced apoptosis occurred normally in lpr granulocytes but were suppressed by G-CSF treatment or Bcl-2 overexpression. Although activation of p38 MAPK has been implicated in granulocyte death, their apoptosis actually was markedly accelerated by specific inhibitors of this kinase. These results suggest that G-CSF promotes granulocyte survival largely through the Bcl-2–controlled pathway, whereas CD95 regulates a distinct pathway to apoptosis that is not required for either their spontaneous or drug-induced death.
    [Show full text]
  • To Professor Suzanne Cory AC
    Citation for the Award of the Doctor of Laws (Honoris Causa) to Professor Suzanne Cory AC When Suzanne Cory graduated from the Science Faculty at the University of Melbourne molecular biology was in its infancy. In her enthusiasm for this new science she pursued a PhD in Cambridge at the Medical Research Council’s famed Laboratory of Molecular Biology. Immersed in a culture of discovery, her pioneering PhD studies determined the sequence of a transfer RNA, utilising new technology developed by Fred Sanger, one of the three Nobel Laureates in the institute. After three years’ post‐doctoral work at the University of Geneva, Suzanne Cory returned to Australia with her husband, Jerry Adams, to the Walter and Eliza Hall Institute of Medical Research where they helped to introduce gene‐cloning technology to Australia. Since then, her long association with the Institute, including thirteen years as Director, and with the University of Melbourne, has been instrumental in building the international reputation of both institutions and the strength of the Parkville biomedical research network. Suzanne Cory has made major contributions to advancing the science of immunology, cancer and genetics, in a lifelong dynamic research partnership with Adams. Her work is published widely and cited frequently. The positions held by the many PhD candidates and Post‐Doctoral Fellows she has supervised demonstrate her intergenerational influence in developing scientific leaders for the future. The list of accolades and awards Suzanne Cory has received in recognition of her contributions to science is long and distinguished. She was elected a Fellow of the Australian Academy of Science in 1986 and since has been elected to numerous sister organisations across the globe.
    [Show full text]
  • Huzzah to the Double Helix! It's International DNA Day | Lifehacker
    Huzzah To The Double Helix! It’s International DNA Day | L... http://www.lifehacker.com.au/2013/04/huzzah-to-the-double-h... Business Insider Gizmodo Kotaku Lifehacker PopSugar BellaSugar FabSugar ShopStyle Log In Register Life Work IT Pro RECENTLY ON KOTAKU RECENTLY ON KOTAKU Robin Has A Point In These Hilarious Conference Or Not, We’ll Cherish Superhero Texts These E3 Nintendo Memes Forever HOME Huzzah To The Double Helix! It’s International DNA Day CHRIS JAGER YESTERDAY 9:30 AM Share 5858 Discuss 22 Today is International DNA Day, which this year commemorates 60 years since the scientific paper A Structure for Deoxyribose Nucleic Acid was first published. Here’s what some of Australia’s leading scientists SUBSCRIBE have to say about the importance of the discovery… CONTACT DNA picture from Shutterstock Sixty years ago to the day, James Watson and Francis Crick published a revolutionary paper on the Like Lifehacker Australia 5,616 Followers structure of Deoxyribonucleic acid; the molecular key to all living things otherwise known as DNA. A Follow Lifehacker Australia 11,734 Followers century after Gregor Mendel first began messing about with peas, the final piece of the genetic puzzle had been slotted into place. Subscribe to all stories 15,269 Followers To mark this historic occasion, several Australian scientists have released statements in which they Australian stories 1,859 Followers basically wax lyrical about the wonders of DNA — what better way to start your morning? (And if you’re wondering what the Lifehacker angle is, the answer is quite simple: when someone smarter than you has something to say, it’s usually worth listening!) REGULARS LIFE Professor Suzanne Cory, President of the Australian Academy of Science: Sell Your Stuff And Get Some Extra Cash This Weekend The discovery of the structure of DNA by James Watson and Francis Crick was an epic moment in the history of science.
    [Show full text]
  • Graeme Laver (Graeme) Ph.D
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Virology 385 (2009) vii–viii Contents lists available at ScienceDirect Virology journal homepage: www.elsevier.com/locate/yviro Obituary William Graeme Laver (Graeme) Ph.D. FRS 1929–2008 the depression and they moved to Melbourne where Graeme attended Ivanhoe Grammar School. At the age of 16 Graeme began work as a “bottle washer” and general laboratory helper at the Hall Institute and matriculated (graduated) by attending night school. He continued working at the Hall Institute and supported himself through Melbourne University graduating with a BSc. Subsequently he did an MSc in biochemistry at Melbourne University and was supported in his PhD at London University by a Commonwealth Scientific and Industrial Research Organization (CSIRO) scholarship. Throughout his entire life Graeme was an adventurer; during his student years as a mountaineer he met his wife, Judy. After completing his PhD in London he and Judy in 1955 drove a small “Standard 10” (English Standard Motor Company) across country back to Australia through Europe, Turkey, Iran, Afghanistan, Pakistan and India to Mumbai (Bombay) then by ship to Australia. They camped en route and were occasionally advised to move on due to bandits and “enjoyed” whole legs of camel, and as guests of honor the eyeballs at impromptu feasts. Upon arrival in Mumbai Graeme found a letter at the post office from Frank Fenner offering him a job at the John Curtin School of Medical Research at the Australia National University (ANU) in Canberra, Australia.
    [Show full text]
  • A Null C-Myc Mutation Causes Lethality Before 10.5 Days of Gestation in Homozygotes and Reduced Fertility in Heterozygous Female Mice
    Downloaded from genesdev.cshlp.org on October 6, 2021 - Published by Cold Spring Harbor Laboratory Press A null c-myc mutation causes lethality before 10.5 days of gestation in homozygotes and reduced fertility in heterozygous female mice Ann C. Davis, 1 Marie Wims, 1 Gerald D. Spotts, 2 Stephen R. Hann, 2 and Allan Bradley 1 tlnstitute for Molecular Genetics, Baylor College of Medicine, Houston, Texas 77030 USA; ~Department of Cell Biology, Vanderbilt University, School of Medicine, Nashville, Tennessee 37232-2175 USA To directly assess c-myc function in cellular proliferation, differentiation, and embryogenesis, we have used homologous recombination in embryonic stem cells to generate both heterozygous and homozygous c-myc mutant ES cell lines. The mutation is a null allele at the protein level. Mouse chimeras from seven heterozygous cell lines transmitted the mutant allele to their offspring. The analysis of embryos from two clones has shown that the mutation is lethal in homozygotes between 9.5 and 10.5 days of gestation. The embryos are generally smaller and retarded in development compared with their littermates. Pathologic abnormalities include the heart, pericardium, neural tube, and delay or failure in turning of the embryo. Heterozygous females have reduced fertility owing to embryonic resorption before 9.5 days of gestation in 14% of implanted embryos, c-Myc protein is necessary for embryonic survival beyond 10.5 days of gestation; however, it appears to be dispensable for cell division both in ES cell lines and in the the embryo before that time. [Key Words: c-myc; gene targeting; null mutation~ embryonic lethal] Received November 25, 1992; revised version accepted January 25, 1993.
    [Show full text]
  • Islet Antibody‐Negative
    Bhatia Vijayalakshmi (Orcid ID: 0000-0003-4683-664X) Dabadghao Preeti (Orcid ID: 0000-0003-0395-7812) Bhatia Eesh (Orcid ID: 0000-0001-7214-7640) High prevalence of idiopathic (islet-antibody negative) type 1 diabetes among Indian children and adolescents Islet-antibody negative type 1 diabetes Valam Puthussery Vipin 1, Ghazala Zaidi 1, Kelly Watson 3, Peter Colman 3, Swayam Prakash 2, Suraksha Agarwal 2, Vijayalakshmi Bhatia1, Preeti Dabadghao1, Eesh Bhatia 1 Department of Endocrinology1 and Medical Genetics2, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India and Department of Diabetes and Endocrinology, Royal Melbourne Hospital, Victoria, Australia3 Corresponding author: Eesh Bhatia, MD Department of Endocrinology Sanjay Gandhi Postgraduate Institute of Medical Sciences Lucknow 226014, India This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/pedi.13066 This article is protected by copyright. All rights reserved. E mail: [email protected] Author contributions VPV: conducted the study, analysed the data, wrote the manuscript EB: conceived, analysed the data, reviewed the manuscript GZ: conducted the testing, analysed data, reviewed manuscript KW: conducted and interpreted the assays, reviewed the manuscript PC: Interpreted the assays, reviewed the manuscript SP: Conducted the testing, analysed and interpreted data SA: Interpreted assays, reviewed the manuscript VB, PD: conducted the study, reviewed the manuscript Conflict of interest statement Authors of this manuscript do not have any conflicts of interest Acknowledgments This work was supported by an intramural grant from Sanjay Gandhi Postgraduate Institute of Medical Sciences to Dr Eesh Bhatia.
    [Show full text]
  • Master Prog Centenary Symposium.Indd
    Influenza 2018: Centenary of the 1918 Pandemic Sunday 24th - Tuesday 26th June 2018 Francis Crick Institute, London UK Programme Sunday 24 June 16.00 - 16.25 Welcome Welcome John Skehel and John McCauley Francis Crick Institute, London, UK Welcome Address Tedros Adhanom Ghebreyesus Director General, WHO, Geneva, Switzerland (TBC) 16.25 - 18.25 Session 1 Chair Robert Webster St. Jude Children’s Research Hospital, Memphis, TN, USA 16.25 - 17.05 Keynote Lecture THEN AND NOW Sally Davies Chief Medical Officer for England, London, UK 17.05 - 17.45 INFLUENZA PANDEMICS OF THE LAST CENTURY Robert Webster St. Jude Children’s Research Hospital, Memphis, TN, US 17.45 - 18.25 LESSONS FROM THE 1918 VIRUS Jeffrey Taubenberger NIAID, Bethesda, MD, USA 18.30 - 19.30 DRINKS RECEPTION Manby Gallery, Francis Crick Institute 1 Monday 25 June 09.00 - 10.45 Session 2 Virus Infection/Replication Chair Robert Lamb, HHMI Northwestern University, Evanston, IL, USA 09.00 - 09.15 Introduction INFLUENZA VIRUS ENTRY INTO CELLS AND ASSEMBLY: AN OVERVIEW Robert Lamb, HHMI Northwestern University, Evanston, IL, USA 09.15 - 09.45 IMAGING INFLUENZA VIRUS MEMBRANE FUSION Peter Rosenthal Francis Crick Institute, London, UK 09.45 - 10.15 CAP-SNATCHING AND HOST-VIRAL INTERACTIONS IMPACTING VIRAL RNA SYNTHESIS Robert Krug University of Texas, Austin, TX, USA 10.15 - 10.45 FLU-VISION: TOTAL IMAGING SYSTEMS FOR ANALYZING INFLUENZA VIRUS INFECTION Yoshi Kawaoka University of Wisconsin, Madison, WI, USA and University of Tokyo, Tokyo, Japan 10.45 - 11.15 TEA / COFFEE BREAK & VIEWING
    [Show full text]
  • 2010-2011 Annual Report
    Annual Report 2010-2011 Mastery of disease through discovery | www.wehi.edu.au Contents 1 About the institute 3 Director’s and Chairman’s report 5 Discovery 8 Cancer and Haematology 10 Stem Cells and Cancer 12 Molecular Genetics of Cancer 14 Chemical Biology 16 Molecular Medicine 18 Structural Biology 20 Bioinformatics 22 Infection and Immunity 24 Immunology The Walter and Eliza Hall Institute 26 Autoimmunity and Transplantation of Medical Research 28 Cell Signalling and Cell Death 1G Royal Parade 30 Inflammation Parkville Victoria 3052 Australia Telephone: (+61 3) 9345 2555 32 Molecular Immunology Facsimile: (+61 3) 9347 0852 34 Publications WEHI Biotechnology Centre 36 Awards 4 Research Avenue 37 Translation La Trobe R&D Park Bundoora Victoria 3086 Australia Translating our research 38 Telephone: (+61 3) 9345 2200 40 Developing our research Facsimile: (+61 3) 9345 2211 42 Patents www.wehi.edu.au www.facebook.com/WEHIresearch 43 Education www.twitter.com/WEHI_research 46 2010-11 graduates ABN 12 004 251 423 47 Seminars Acknowledgements 48 Institute awards Produced by the institute’s Community Relations department 49 Engagement Managing editor: Penny Fannin Editor: Liz Williams 51 Strategic partners Writers: Liz Williams, Vanessa Solomon and Julie Tester 52 Scientific and medical community Design and production: Simon Taplin Photography: Czesia Markiewicz and Cameron Wells 54 Public engagement 57 Engagement with schools Cover image 58 Donor and bequestor engagement Art in Science finalist 2010 Vessel webs 59 Sustainability Dr Leigh Coultas, Cancer and Haematology division 60 The Board This image shows the delicate intricacy in the developing eye of a transient population of web-like blood vessels.
    [Show full text]
  • Survey of Commercial Outcomes from Public Research (Scopr) 2019 Report
    techtransfer.org.au SURVEY OF COMMERCIAL OUTCOMES FROM PUBLIC RESEARCH (SCOPR) 2019 REPORT Survey and report delivered by FOREWORD There is an ever-present imperative to capture the commercial value of our research endeavour for our future wellbeing. To do so strategically, decision makers from laboratory, institutional and government levels need insights into how the research sector is currently engaging with industry to transfer knowledge and innovation, and thereby deliver benefits to our society from the fruits of our research. For many years in Australia there has been a focus on improving innovation metrics, thus I am delighted to acknowledge the initiative of gemaker and Knowledge Commercialisation Australasia (KCA) in producing the inaugural Survey of Commercial Outcomes from Public Research (SCOPR). The SCOPR takes its lead from the National Survey of Research Commercialisation (NSRC) produced since 2000 by the Department of Industry, Science, Energy and Resources. To avoid duplication, the Department has decided to cease the NSRC and will work with KCA to share knowledge, and access data collected by SCOPR. As we face the COVID-19 pandemic, effective knowledge transfer is more important than ever, so I hope that this report will spur our research institutions to even greater achievements. Realising effective knowledge transfer will depend on having skilled commercialisation professionals who can help researchers turn great ideas into beneficial products and services. I applaud KCA’s support for technology transfer professionals
    [Show full text]
  • Expression of the Other in T Cells Bim and Bcl-2 Mutually Affect
    Bim and Bcl-2 Mutually Affect the Expression of the Other in T Cells Trine N. Jorgensen, Amy McKee, Michael Wang, Ella Kushnir, Janice White, Yosef Refaeli, John W. Kappler and This information is current as Philippa Marrack of September 25, 2021. J Immunol 2007; 179:3417-3424; ; doi: 10.4049/jimmunol.179.6.3417 http://www.jimmunol.org/content/179/6/3417 Downloaded from References This article cites 54 articles, 22 of which you can access for free at: http://www.jimmunol.org/content/179/6/3417.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 25, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2007 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Bim and Bcl-2 Mutually Affect the Expression of the Other in T Cells1 Trine N. Jorgensen,2* Amy McKee,2*ʈ Michael Wang,2† Ella Kushnir,*ʈ Janice White,*ʈ Yosef Refaeli,** John W.
    [Show full text]
  • The Bio21 Institute's 2020 Annual Report Is Available to Download
    Annual Report 2020 Image of the coronavirus SARS-CoV-2 taken by Andrew Leis and Jason Roberts. Courtesy of the Doherty Institute. The Bio21 Molecular Science and Director Associate Director – Platform Biotechnology Institute Professor Michael W. Parker Infrastructure University of Melbourne DPhil (Oxon) FAA FAHMS Professor Malcolm McConville PhD 30 Flemington Road Deputy Director Associate Director – Commercialisation Parkville Victoria 3010 Professor Frances Separovic AO Professor Spencer Williams PhD Telephone: (03) 8344 2220 PhD FAA www.bio21.unimelb.edu.au Associate Director – Engagement @Bio21Institute Professor Sally Gras PhD @Bio21Institute Scientific Research Manager Dr David Keizer, PhD Produced by the Bio21 Molecular Science and Biotechnology External Relations Advisor,b Bio21 Florienne Institute Loder Annual Report 2020 Contents Our Mission 2 Our Vision 2 About the Institute 3 Director’s Message 4 Bio21 Leadership 8 Deputy Director, Professor Emeritus Frances Separovic AO 8 Associate Director Engagement – Professor Sally Gras 10 Associate Director Commercialisation – Professor Spencer Williams 13 Associate Director Platform Infrastructure – Professor Malcolm McConville 14 ACRF Facility for Innovative Cancer Drug Discovery 16 Impacts of Research 19 OHS Report 31 Equity Diversity and Inclusion 32 Industry Engagement and Commercialisation 35 Announcing the Ruth Bishop Building and Ian Holmes Imaging Centre 36 Events and Conferences 39 Graduate Research Students and Early Career Researchers 41 Institute Members Honoured 42 Grant Successes 43 Governance 46 Bio21 Scientific Research Team 47 Bio21 Research Groups 48 Bio21 People 50 Institute in Numbers 56 Bio21 Institute Theses submitted in 2020 57 Bio21 Steering Committee 58 Industry partners 63 Produced by the Bio21 Molecular Science aFontn Front cover image: Bio21 precinct aerial photograph, courtesy of Kane Jarrod Photography.
    [Show full text]